Xenon Pharmaceuticals
XENE
180 hedge funds and large institutions have $2.1B invested in Xenon Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 71 increasing their positions, 50 reducing their positions, and 15 closing their positions.
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
42% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 50
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
3% more funds holding
Funds holding: 175 → 180 (+5)
0.84% less ownership
Funds ownership: 96.48% → 95.63% (-0.84%)
11% less capital invested
Capital invested by funds: $2.36B → $2.1B (-$264M)
43% less call options, than puts
Call options by funds: $10.9M | Put options by funds: $19.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$38.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.3M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$18.8M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$35M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$30.3M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$26.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$22.7M |
| 5 |
Holocene Advisors
New York
|
-$20M |
XENE Hedge Fund Activity: Q3 2023 in Review
180 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2023, worth a combined $2.1B — down 11% from $2.36B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XENE positions and 15 closed out — a net gain of 7 holders — while 71 added to existing stakes and 50 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $38.1M. The largest seller was Fidelity Investments, cutting an estimated $35M.
- 180 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2023, up from 175 in Q2 2023.
- Funds reported $2.1B of Xenon Pharmaceuticals stock for Q3 2023, down 11% quarter-over-quarter.
- 22 funds opened new Xenon Pharmaceuticals positions in Q3 2023 and 15 closed out, a net change of +7 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2023 was AllianceBernstein, an estimated $38.1M added.
- The largest Xenon Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $35M sold.
Based on aggregated 13F filings for Q3 2023.